JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB146428

SC79, Akt activator

Be the first to review this product! Submit a review

|

(9 Publications)

MW 364.8 g/mol, Purity 98%. Akt activator. Binds to the pleckstrin homology domain. Suppress excitotoxicity-induced neuronal death. Shows neuroprotective effects in vivo. Blood-brain barrier permeable.
1 Images
Chemical Structure - SC79, Akt activator (AB146428)
  • Chemical Structure

Lab

Chemical Structure - SC79, Akt activator (AB146428)

2D chemical structure image of ab146428, SC79, Akt activator

Key facts

CAS number

305834-79-1

Purity

98%

Form

Solid

form

Molecular weight

364.8 g/mol

Molecular formula

C<sub>1</sub><sub>7</sub>H<sub>1</sub><sub>7</sub>ClN<sub>2</sub>O<sub>5</sub>

Nature

Synthetic

Solubility

Soluble in DMSO (100mg/mL)

Soluble in ethanol (40mg/mL, warm)

Biological description

Akt activator. Binds to the pleckstrin homology domain. Suppress excitotoxicity-induced neuronal death. Shows neuroprotective effects in vivo. Blood-brain barrier permeable.

Isomeric smiles

CCOC(=O)C1=C(OC2=C(C1C(C#N)C(=O)OCC)C=C(C=C2)Cl)N

IUPAC Name

2-Amino-6-chloro-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester

style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column
style
left-column
style
left-column

Product protocols

style
left-column

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

PeerJ 12:e17555 PubMed38948215

2024

PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Tianzi Qin,Minyu Huang,Wenjuan Wei,Wei Zhou,Qianli Tang,Qun Huang,Ning Tang,Shasha Gai

Oncology letters 22:828 PubMed34691255

2021

Silencing of NACC1 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells via regulating the AKT/mTOR signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Zhengyong Cao,Hong Chen,Xiaoli Mei,Xiaobo Li

Scientific reports 11:18384 PubMed34526601

2021

Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.

Applications

Unspecified application

Species

Unspecified reactive species

Masaaki Nakao,Ippei Shimizu,Goro Katsuumi,Yohko Yoshida,Masayoshi Suda,Yuka Hayashi,Ryutaro Ikegami,Yung Ting Hsiao,Shujiro Okuda,Tomoyoshi Soga,Tohru Minamino

Molecular medicine reports 23: PubMed33880579

2021

Germacrone induces lung cancer cell apoptosis and cell cycle arrest via the Akt/MDM2/p53 signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yang Zhao,Jie Cai,Kaihu Shi,Hang Li,Jin Du,Dinghui Hu,Zuntao Liu,Wei Wang

International journal of molecular sciences 20: PubMed31581662

2019

Temporal Effects of Quercetin on Tight Junction Barrier Properties and Claudin Expression and Localization in MDCK II Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Enrique Gamero-Estevez,Sero Andonian,Bertrand Jean-Claude,Indra Gupta,Aimee K Ryan

Clinical science (London, England : 1979) 133:1167-1184 PubMed31076460

2019

Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.

Applications

Unspecified application

Species

Unspecified reactive species

Zhongzheng Sun,Hao Xue,Yan Wei,Chaochao Wang,Rui Yu,Chengwei Wang,Shaobo Wang,Jianye Xu,Mingyu Qian,Qinghu Meng,Gang Li

Cancer management and research 11:3813-3828 PubMed31118799

2019

lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Fan Wang,Xun Qi,Zixuan Li,Shiqi Jin,Yang Xie,Hongshan Zhong

Oncology reports 40:3458-3468 PubMed30542737

2018

Pectolinarigenin inhibits non‑small cell lung cancer progression by regulating the PTEN/PI3K/AKT signaling pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Fei Xu,Xuan Gao,Huiyun Pan

International journal of endocrinology 2018:4371396 PubMed29853881

2018

Beta-Arrestin 1 Mediates Liver Thyrotropin Regulation of Cholesterol Conversion Metabolism via the Akt-Dependent Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Shaona Niu,Hui Li,Wenbin Chen,Jiajun Zhao,Ling Gao,Tao Bo
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB142088

Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor

Chemical Structure - Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor (AB142088)

  • 0
  • 0
Primary Antibodies

AB38449

Anti-AKT (phospho T308) antibody

Lab Essentials

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT (phospho T308) antibody (AB38449)

  • 3
  • 5
Primary Antibodies

AB7817

Anti-alpha smooth muscle Actin antibody [1A4]

KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-alpha smooth muscle Actin antibody [1A4] (AB7817)

  • 5
  • 105
Primary Antibodies

AB278545

Anti- PI 3 Kinase p85 alpha (phospho Y467) + PI3 Kinase p55 (phospho Y199) antibody [PI3KY458-1A11]

20ul selling size|Recombinant

Flow Cytometry - Anti- PI 3 Kinase p85 alpha (phospho Y467) + PI3 Kinase p55 (phospho Y199) antibody [PI3KY458-1A11] (AB278545)

  • 5
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com